Cleveland, OH, United States
Cleveland, OH, United States

Time filter

Source Type

Werner-Wasik M.,Thomas Jefferson University | Nelson A.D.,MIM Software Inc. | Choi W.,UPMC Health Systems | Arai Y.,Beth Israel Deaconess Medical Center | And 8 more authors.
International Journal of Radiation Oncology Biology Physics | Year: 2012

Purpose: To evaluate the accuracy and consistency of a gradient-based positron emission tomography (PET) segmentation method, GRADIENT, compared with manual (MANUAL) and constant threshold (THRESHOLD) methods. Methods and Materials: Contouring accuracy was evaluated with sphere phantoms and clinically realistic Monte Carlo PET phantoms of the thorax. The sphere phantoms were 10-37 mm in diameter and were acquired at five institutions emulating clinical conditions. One institution also acquired a sphere phantom with multiple source-to-background ratios of 2:1, 5:1, 10:1, 20:1, and 70:1. One observer segmented (contoured) each sphere with GRADIENT and THRESHOLD from 25% to 50% at 5% increments. Subsequently, seven physicians segmented 31 lesions (7-264 mL) from 25 digital thorax phantoms using GRADIENT, THRESHOLD, and MANUAL. Results: For spheres <20 mm in diameter, GRADIENT was the most accurate with a mean absolute % error in diameter of 8.15% (10.2% SD) compared with 49.2% (51.1% SD) for 45% THRESHOLD (p < 0.005). For larger spheres, the methods were statistically equivalent. For varying source-to-background ratios, GRADIENT was the most accurate for spheres >20 mm (p < 0.065) and <20 mm (p < 0.015). For digital thorax phantoms, GRADIENT was the most accurate (p < 0.01), with a mean absolute % error in volume of 10.99% (11.9% SD), followed by 25% THRESHOLD at 17.5% (29.4% SD), and MANUAL at 19.5% (17.2% SD). GRADIENT had the least systematic bias, with a mean % error in volume of -0.05% (16.2% SD) compared with 25% THRESHOLD at -2.1% (34.2% SD) and MANUAL at -16.3% (20.2% SD; p value <0.01). Interobserver variability was reduced using GRADIENT compared with both 25% THRESHOLD and MANUAL (p value <0.01, Levene's test). Conclusion: GRADIENT was the most accurate and consistent technique for target volume contouring. GRADIENT was also the most robust for varying imaging conditions. GRADIENT has the potential to play an important role for tumor delineation in radiation therapy planning and response assessment. © 2012 Elsevier Inc.


News Article | November 27, 2016
Site: globenewswire.com

PEABODY, Mass., Nov. 27, 2016 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will introduce bkFusion1, a groundbreaking solution for improving biopsy targeting in prostate cancer, at the 102nd Annual Meeting of the Radiological Society of North America (RSNA). bkFusion is the latest innovation from the company’s flagship BK Ultrasound brand. It is the first MR-fusion biopsy application, fully integrated into BK Ultrasound’s bk3000 premium ultrasound system designed uniquely for use by urologists for both hospital and office settings. Targeting subtle prostate lesions for biopsy is difficult with ultrasound alone. bkFusion seamlessly overlays MR image information about lesion location and extent onto real-time ultrasound images, without the need for an additional workstation. This improves workflow and minimizes the system’s footprint, which are significant benefits for the urologist performing biopsies in the office, enabling faster and more reliable disease management. BK Ultrasound, powered by Analogic, has partnered with MIM Software Inc., a provider of market-leading imaging solutions for radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging, to create bkFusion. The innovative software builds on MIM’s unique Predictive Fusion technology to enable the urologist to precisely biopsy MR-defined targets in less time and with more accuracy than a traditional ultrasound-only biopsy approach. With its small footprint, the bk3000 fits easily into any office space and because bkFusion is completely integrated on the ultrasound system, no additional bulky equipment or set-up time is required. The system communicates easily with radiology departments, accessing the MR images via PACS or a secure cloud platform. “We are very pleased to launch a ground-breaking new solution for the Urology community in partnership with MIM” said Jacques Coumans PhD, VP, chief marketing & scientific officer. “Our customers are our best guide for break-through innovation. Complementing MIM’s leadership in medical image processing for cancer visualization with our strength in specialty ultrasound has created a solution our customers have been looking for. Current solutions for MR-fusion have had MR at the center of the workflow. With bkFusion, we put real-time ultrasound as the focus of our Urology-centered approach. The MR information helps point urologists more precisely to their target, and the prostate image quality provided by the bk3000 helps urologists visualize and revalidate subtle lesions.” “We are excited to partner with BK Ultrasound to bring this innovative application to Urology,” said, Jon Piper, VP of R&D from MIM. “bkFusion makes it possible to harness the power of MR imaging in the Urology office, providing patients with the clinical benefits of a more targeted biopsy in the privacy and comfort of their physician’s practice setting. Our approach has always been to focus on technology that benefits the greatest number of patients possible by being practical for use in centers of any size.” Analogic will also showcase its newest innovative products that deliver to OEMs breakthrough reliability and lowest cost of ownership in their CT, MRI, and digital mammography offerings. Featured products will include its 64-slice, 85-cm bore CT gantry, equipped with LISA (Low Dose Imaging Software by Analogic); its latest 1.5T RF amplifier for MRI; and its newest Selenium-based, direct-digital detector for mammography. Visit Analogic at Booth #6124 during RSNA 2016. More information may be found at www.analogic.com. About Analogic Analogic (Nasdaq:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI) and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com. Analogic and the globe logo are registered trademarks, and BK Ultrasound and bkFusion are trademarks, of Analogic Corporation or its affiliated companies.


News Article | November 9, 2016
Site: www.newsmaker.com.au

The report "Medical Image Analysis Software Market by Type (Integrated, Standalone), Image (2D, 3D, 4D), Modality (CT, MRI, PET, Ultrasound, Radiography), Application (Orthopedic, Oncology, Nephrology), End User (Hospital, Research Center) - Global Forecasts to 2020" ,analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW). Browse 308 market data Tables and 64 Figures spread through 312 Pages and in-depth TOC on "Medical Image Analysis Software Market by Type (Integrated, Standalone), Image (2D, 3D, 4D), Modality (CT, MRI, PET, Ultrasound, Radiography), Application (Orthopedic, Oncology, Nephrology), End User (Hospital, Research Center) - Global Forecasts to 2020" http://www.marketsandmarkets.com/Market-Reports/medical-image-analysis-software-market-846.html Early buyers will receive 10% customization on reports. The global medical image analysis software market is expected to reach USD 3,135.3 Million by 2020 from USD 2,143.7 Million in 2015, at a CAGR of 7.9% during the forecast period. Growth in this market is mainly driven by factors such as technological advancements, growing public- and private-sector investments, rapid growth in aging population, fusion of imaging technologies, growing applications of computer-aided diagnosis (CAD), rising incidence of chronic diseases, and increasing usage of imaging equipment. Moreover, factors such as rising demand for automated image analysis techniques, growing impact of cloud-based solutions, and untapped emerging markets are expected to offer significant growth opportunities to players operating in the medical image analysis software market. However, financial constraints, growing hacking-related risks associated with the use of medical equipment and software, and dearth of skilled professionals are expected to restrain the growth of this market in the coming years. This report segments the medical image analysis software market based on software type, image type, modality, application, end user, and region. Based on software type, the medical image analysis software market is segmented into integrated and standalone software. The integrated software segment is expected to account for the largest market share in 2015, primarily due to the growing adoption of imaging systems. Based on region, the medical image analysis software market is segmented into North America, Europe, Asia, and Rest of the World (RoW). The North American market is subsegmented into the U.S. and Canada; the European market is subsegmented into Germany, France, the U.K., and Rest of Europe (RoE); and the Asian market is subsegmented into Japan, China, India, and Rest of Asia (RoA). In 2015, North America is expected to dominate the market, followed by Europe. Major factors such as rising geriatric population, technological advancements, and favorable reimbursement policies are driving the medical image analysis software market in North America. However, the Asian market is expected to witness higher growth in the coming years, majorly due to the increasing government initiatives for the modernization of healthcare infrastructure, growth in the number of new and advanced products being launched in emerging Asian countries, and rising number of ongoing research activities. The medical image analysis software market is highly fragmented, with several big and emerging players operating in the market. Some of the key market players include Agfa HealthCare (Belgium), Aquilab (France), Carestream Health, Inc. (U.S.), Esaote S.p.A (Italy), GE Healthcare (U.K.), Merge Healthcare, Inc. (U.S.), MIM Software Inc. (U.S.), Philips Healthcare (Netherlands), Siemens Healthcare (Germany), and Toshiba Medical Systems Corporation (Japan).


PubMed | Thomas Jefferson University, University of Pennsylvania, Ohio University, MIM Software Inc. and 2 more.
Type: Journal Article | Journal: Medical physics | Year: 2017

To establish a workflow for NRG-GY006 IMRT pre-treatment reviews, incorporating advanced radiotherapy technologies being evaluated as part of the clinical trial.Pre-Treatment reviews are required for every IMRT case as part of NRG-GY006 (a randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage I B2, stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer. The pretreatment review process includes structures review and generating an active bone marrow(ABM)- to be used as an avoidance structure during IMRT optimization- and evaluating initial IMRT plan quality using knowledgeengineering based planning (KBP). Institutions will initially submit their simulation CT scan, structures file and PET/CT to IROC QA center for generating ABM. The ABM will be returned to the institution for use in planning. Institutions will then submit an initial IMRT plan for review and will receive information back following implementation of a KBP algorithm, for use in re-optimization, before submitting the final IMRT used for treatment.ABM structure is generated using MIM vista software (Version 6.5, MIM corporation, Inc.). Here, the planning CT and the diagnostic PET/CT are fused and a sub threshold structure is auto segmented above the mean value of the SUV of the bone marrow. The generated ABM were compared with those generated with other software system (e.g. Velocity, Varian) and Dice coefficient (reflects the overlap of structures) ranged between 80 - 90% was achieved. A KBP model was built in Varian Eclipse TPS using the RapidPlan KBP software to perform plan quality assurance.The workflow for IMRT pretreatment reviews has been established. It represents a major improvement of NRG Oncology clinical trial quality assurance and incorporates the latest radiotherapy technologies as part of NCI clinical trials. This project was supported by grants U24CA180803 (IROC), UG1CA189867 (NCORP), U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC) from the National Cancer Institute (NCI) and PA CURE grant.


Oborski M.J.,University of Pittsburgh | Laymon C.M.,University of Pittsburgh | Qian Y.,University of Pittsburgh | Lieberman F.S.,University of Pittsburgh | And 2 more authors.
Translational Oncology | Year: 2014

Evaluation of cancer-therapy efficacy at early time points is necessary for realizing the goal of delivering maximally effective treatment. Molecular imaging with carefully selected tracers and methodologies can provide the means for realizing this ability. Many therapies are aimed at inducing apoptosis in malignant tissue; thus, the ability to quantify apoptosis in vivo may be a fruitful approach. Apoptosis rate changes occur on a fast time scale, potentially allowing correspondingly rapid decisions regarding therapy value. However, quantification of tissue status based on apoptosis imaging is complicated by this time scale and by the spatial heterogeneity of the process. Using the positron emission tomography (PET) tracer 2-(5-fluoro-pentyl)-2-methyl-malonic acid (F-18 ML-10), we present methods of voxelwise analysis yielding quantitative measures of apoptosis changes, parametric apoptosis change images, and graphical representation of apoptotic features. A method of deformable registration to account for anatomic changes between scan time points is also demonstrated. Overall apoptotic rates deduced from imaging depend on tumor density and the specific rate of apoptosis, a situation resulting in an ambiguity in the source of observed image-based changes. The ambiguity may be resolved through multimodality imaging. An example of intracellular sodium magnetic resonance imaging coupled with F-18 ML-10 PET is provided. © 2014 Neoplasia Press, Inc. All rights reserved.


Patent
MIM Software Inc. | Date: 2015-04-10

In accordance with the teachings described herein, systems and methods are provided for generating images for use in systems, e.g., imaging systems. The method includes receiving at least a first set of images, providing a first registration, providing a display, and displaying a first image on said display. Further, the method includes providing a user interface, providing a second registration, and displaying a second image in said user interface. Further, the systems include an image database, a display, and a registration engine. The registration engine includes software instructions stored in at least one memory device and executable by one or more processors.


Patent
MIM Software Inc. | Date: 2012-09-21

In accordance with the teachings described herein, systems and methods are provided for generating images for use in systems, e.g., imaging systems. The method includes receiving at least a first set of images, providing a first registration, providing a display, and displaying a first image on said display. Further, the method includes providing a user interface, providing a second registration, and displaying a second image in said user interface. Further, the systems include an image database, a display, and a registration engine. The registration engine includes software instructions stored in at least one memory device and executable by one or more processors.


Mim

Trademark
MIM Software Inc. | Date: 2012-07-31

Computer software for use in medical image processing in the field of radiology.


Patent
Mim Software Inc. | Date: 2013-03-15

A registration technique is provided that can combine one or more related registrations to enhance accuracy of a registration of image volumes. A registration relationship between a first source volume and a target volume and a registration relationship between the first source volume and a second source volume are concatenated to provide an estimate of a registration relationship between the second source volume and the target volume. The estimate is utilized to inform the direct registration of the second source volume to the target volume or utilized in place of the direct registration.


PubMed | University of Miami and MIM Software Inc.
Type: Journal Article | Journal: Medical physics | Year: 2017

Automatically generated prostate MRI contours can be used to aid in image registration with CT or ultrasound and to reduce the burden of contouring for radiation treatment planning. In addition, prostate and zonal contours can assist to automate quantitative imaging features extraction and the analyses of longitudinal MRI studies. These potential gains are limited if the solutions are not compatible across different MRI vendors. The goal of this study is to characterize an atlas based automatic segmentation procedure of the prostate collected on MRI systems from multiple vendors.The prostate and peripheral zone (PZ) were manually contoured by an expert radiation oncologist on T2-weighted scans acquired on both GE (n=31) and Siemens (n=33) 3T MRI systems. A leave-one-out approach was utilized where the target subject is removed from the atlas before the segmentation algorithm is initiated. The atlas-segmentation method finds the best nine matched atlas subjects and then performs a normalized intensity-based free-form deformable registration of these subjects to the target subject. These nine contours are then merged into a single contour using Simultaneous Truth and Performance Level Estimation (STAPLE). Contour comparisons were made using Dice similarity coefficients (DSC) and Hausdorff distances.Using the T2 FatSat (FS) GE datasets the atlas generated contours resulted in an average DSC of 0.830.06 for prostate, 0.570.12 for PZ and 0.750.09 for CG. Similar results were found when using the Siemens data with a DSC of 0.790.14 for prostate, 0.540.16 and 0.700.9. Contrast between prostate and surrounding anatomy and between the PZ and CG contours for both vendors demonstrated superior contrast separation; significance was found for all comparisons p-value < 0.0001.Atlas-based segmentation yielded promising results for all contours compared to expertly defined contours in both Siemens and GE 3T systems providing fast and automatic segmentation of the prostate. Funding Support, Disclosures, and Conflict of Interest: AS Nelson is a partial owner of MIM Software, Inc. AS Nelson, and A Swallen are current employees at MIM Software, Inc.

Loading MIM Software Inc. collaborators
Loading MIM Software Inc. collaborators